Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer

Clinical trial NCT04836728 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04836728
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Metastatic First-line Treatment

Start date: 2021-03-31
Primary completion: 2024-04-30
Enrollment: 156

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.